• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 07, 2022 at 10:32: AM
via Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance recently snagged a heart failure label expansion in the U.S. Now, the drug is widening its cardiovascular reach into Europe, with a nod that could help the med play catch-up with AstraZeneca’s SGLT2 rival Farxiga.

article source
 




Top Bottom
Back
Quote